CLAIMS

1. A compound(s) or its pharmaceutically-acceptable salt(s) as shown by Formula (II),

(II)



R_3 is selected from 5-membered aromatic heterocycles, C_{6-12} aryl groups, and C_{5-12} heteroaromatic rings, wherein R_3 is optionally substituted with from 1 to 3 R_{01} groups;

L_2 is independently selected respectively from



;

m_1 and m_2 are independently selected respectively from 1 or 2;

X_1 and X_2 are independently selected from —$C(R_{d1})(R_{d2})$—, —$N(R_{d4})$—, —$C(=NR_{d5})$—, —O—, —S—, —C(=O)—, —C(=S)—, —S(=O)— or —$S(=O)_2$—;

R_4 is selected from 5-14-membered cycloalkyl, heterocycloalkyl, aryl, heteroaryl, bicyclic, or biaryl groups, wherein R_4 is substituted with R_{01};

R_{d1}, R_{d2}, R_{d4}, and R_{d5} are independently selected respectively from H, F, Cl, Br, I, CN, OH, SH, NH_2, CHO, and COOH;

R_{01} is selected from H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH, R_{02};

R_{02} is selected from C_{1-10} alkyl groups, C_{1-10} alkylamino groups, N,N—(C_{1-10} alkyl) amino groups, C_{1-10} alkoxy groups, C_{1-10} alkanoyl groups, C_{1-10} alkoxycarbonyl groups, C_{1-10} alkylsulfonyl groups, C_{1-10} alkylsulfinyl groups, C_{3-10} cycloalkyl groups, C_{3-10} cycloalkylamino groups, C_{3-10} heterocyclic alkyl amino groups, C_{3-10} cycloalkoxy groups, C_{3-10} cycloalkyl acyl groups, C_{3-10} cycloalkoxy-carbonyl groups, C_{3-10} cycloalkylsulfonyl groups, C_{3-10} cycloalkylsulfinyl groups, C_3H_7—O—N═, CH_3ON═, C_2H_5ON═, C_2H_5ON═CH—, C_3H_5C—O—N═CH—, and C_3H_7—O—N═CH—;

is optionally substituted by 1 to 3 R_{001} groups;

R_{001} is selected from F, Cl, Br, I, CN, OH, $N(CH_3)_2$, $NH(CH_3)$, NH_2, CHO, COOH, trifluoromethyl group, aminomethyl group, hydroxymethyl group, methyl group, methoxy group, formyl group, methoxycarbonyl group, methylsulfonyl group and methylsulfinyl group;

optionally, R_{d1} and R_{d2} interconnect together to form a 3 or 4-membered carbocyclic or heterocyclic ring.

2. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim **1**, wherein Formula (II) is further defined as follows:



3. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



4. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



wherein R_{01} is selected from —H, CH_3, CH_3CONH—, NH_2, $HOCH_2CH_2NH$—, and CH_3NH—;

R_{04} is selected from C_2H_5═O—N═CH—, $C_3H_5CH_2$—O—N═CH—, and C_3H_7—O—N═CH—.

5. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim **1**, wherein Formula (II) is further defined as follows:



Wherein R_{01} is selected from H,NH_2—, $HOCH_2CH_2NH$—, and CH_3NH—;
R_{05} is selected from C_3H_7—O—N═, CH_3═O—N═, and C_2H_5—O—N═.

6. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim **1**, wherein Formula (II) is further defined as follows:



wherein R_{05} is selected from CH_3, C_2H_5, and C_3H_7.

7. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim **1**, wherein Formula (II) is selected from the following

